Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy

Bendamustine-rituximab (BR) therapy has been established as a highly effective regimen for indolent non-Hodgkin lymphoma (NHL). However, patients who receive BR therapy exhibit persistent hypogammaglobulinemia and lymphopenia, resulting in an increased incidence of infections. As a sustained immunos...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Manabu, Koyama, Daisuke, Ikeda, Shohei, Sukegawa, Masumi, Teshirogi, Mayumi, Misawa, Kyohei, Tsunoda, Saburo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JSLRT 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353852/
https://www.ncbi.nlm.nih.gov/pubmed/35153257
http://dx.doi.org/10.3960/jslrt.21031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353852/
https://www.ncbi.nlm.nih.gov/pubmed/35153257
http://dx.doi.org/10.3960/jslrt.21031

Ejemplares similares